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Aim 
To assess the effect of PZA 
resistance upon treatment outcome 
amongst MDR-TB patients treated 
with a full intensive phase PZA 
regimen 
 
To assess the effect of PZA 
treatment duration (full intensive 
phase, partial, incomplete and no 
PZA treatment) upon treatment 
outcome, amongst MDR-TB patients 
with PZA strains of unknown 
resistance 
 
Background 
Pyrazinamide (PZA), is regarded as an important agent in 
the management of multi-drug resistant tuberculosis 
(MDR-TB) (defined as resistance to at least rifampicin and 
isoniazid) and has been shown to reduce treatment 
duration for drug-sensitive TB (1). Since the inclusion of 
PZA in a MDR-TB regimen adds significantly to both the 
pill burden and the side effects, (mainly arthralgia and 
hepatitis), it is logical to limit usage to patients where PZA 
has a proven effect.  
The current World Health Organisation (WHO) 
recommendation is to include PZA in MDR-TB regimens 
unless there is demonstrated evidence of resistance (2). 
However, large-scale data supporting this recommendation 
are lacking.  
 
Results 
Conclusion 
 
Death/Failure 
n (%) 
Success 
n (%) 
Crude OR 
(95% CI) 
p value Adjusted† OR 
(95% CI) 
p value 
112/508*  
(22.0%) 
396/508*  
(78.0%) 
    
Pyrazinamide     
Resistant 80 (22.2%) 280 (77.8%) 1.00     
Susceptible 32 (21.6%) 116 (78.4%) 1.04 (0.65-1.65) 0.9 0.86 (0.51-1.44) 0.6 
Sex     
Female 63 (22.6%) 216 (77.4%) 1.00     
Male 49 (21.4%) 180 (78.6%) 1.07 (0.70-1.63) 0.7 1.04 (0.67-1.61) 0.9 
Age     
Years, median (IQR) 32 (26.0-43.5) 30 (23.5-41.5) 0.99 (0.97-1.00) 0.06 0.99 (0.97-1.00) 0.07 
TB programme             
2003 12 (20.3%) 47 (79.7%) 1.00       
2009 42 (27.1%) 113 (72.9%) 0.69 (0.33-1.42) 0.3 0.58 (0.26-1.29) 0.2 
2012 58 (19.7%) 236 (80.3%) 1.04 (0.52-2.08) 0.9 0.91 (0.41-1.99) 0.8 
Diabetes     
No 90 (21.5%) 328 (78.5%) 1.00     
Yes 9 (37.5%) 15 (62.5%) 0.46 (0.19-1.08) 0.07     
Unknown 13 (19.7%) 53 (80.3%) 1.12 (0.58-2.14) 0.7     
Previous 1st line drugs     
No 18 (14.8%) 104 (85.2%) 1.00     
Yes 94 (24.4%) 292 (75.6%) 0.54 (0.31-0.93) 0.03 0.55 (0.31-0.99) 0.05 
Previous 2nd line drugs           
No 88 (20.4%) 344 (79.6%) 1.00       
Yes 24 (31.6%) 52 (68.4%) 0.55 (0.32-0.95) 0.03     
Cavities on X-ray             
No 26 (18.6%) 114 (81.4%) 1.00       
Yes 86 (23.4%) 282 (76.6%) 0.75 (0.46-1.22) 0.3 0.83 (0.49-1.39) 0.5 
Sputum smear‡             
Negative 18 (12.9%) 121 (87.1%) 1.00       
Scanty/1+ 40 (23.5%) 130 (76.5%) 0.48 (0.26-0.89) 0.02     
2+/3+ 53 (26.9%) 144 (73.1%) 0.40 (0.22-0.73) 0.002     
Number of drugs to which diagnostic strain resistant         
Number, median (IQR) 4 (4-5) 4 (4-4) 0.64 (0.51-0.81) <0.001 0.64 (0.50-0.81) <0.001 
Median potentially effective drugs in intensive phase     
2-4 24 (21.4%) 88 (78.6%) 1.00       
5-6 77 (20.5%) 298 (79.5%) 1.06 (0.63-1.77) 0.8     
7-8 11 (52.4%) 10 (47.6%) 0.25 (0.09-0.65) 0.005     
Table 1 Crude and adjusted analyses of effect of PZA susceptibility and other exposure variables upon treatment 
outcome amongst patients treated with a full intensive phase PZA regimen 
Death/ 
Failure 
n (%) 
Success 
n (%) 
Crude OR 
(95% CI) 
p value Adjusted† OR 
(95% CI) 
p value 
247/1,114* 
(22.2%) 
867/1,114* 
(77.8%) 
Full intensive phase PZA regimen 
Partial (<80%) 18 (18.9%) 77 (81.1%) 1.00 
Full PZA regimen (≥80%) 229 (22.5%) 790 (77.5%) 0.81 (0.47-1.38) 0.4 0.86 (0.49-1.51) 0.6 
PZA treatment length in intensive phase 
None (<16%) 14 (18.4%) 62 (81.6%) 1.00 
Incomplete (≥16% and <80%) 4 (21.1%) 15 (78.9%) 0.85 (0.24-2.94) 0.8 0.80 (0.22-2.94) 0.7 
Full PZA regimen (≥80%) 229 (22.5%) 790 (77.5%) 0.78 (0.43-1.42) 0.4 0.82 (0.43-1.55) 0.5 
Table 2 Crude and adjusted analyses of effect of PZA regimen received upon treatment outcome amongst patients 
with no available PZA DST at diagnosis  
•  No evidence of an association between a successful outcome and PZA susceptibility 
in both crude (OR 1.04, 95% CI 0.65-1.65, p=0.9) and adjusted analysis (OR 0.86, 95% 
CI 0.51-1.44, p=0.6) amongst patients receiving a full intensive phase PZA treatment. 
Adjustment was made for age, sex, previous FLD, cavities on X-ray, programme year 
and number of resistant drugs at diagnosis 
•  No evidence of an association between successful outcome and having received a full 
intensive phase PZA regimen, amongst patients with no available baseline PZA DST at 
diagnosis (OR 0.86, 95% CI 0.49-1.51, p=0.6)  
•  Similar results were seen when comparing patients who were treated with a 
incomplete PZA regimen or a full intensive phase compared to no PZA treatment 
amongst patients with no diagnostic PZA DST. 
No evidence was shown of an association between a successful outcome and PZA susceptibility for 
MDR-TB patients treated with a full intensive phase PZA standard WHO regimen in a high MDR-TB 
burden setting. Furthermore, there was no evidence of a dose-response association between a 
successful outcome and different PZA treatment regimens in the intensive phase. The major limitations 
was the low power for the main analysis and the retrospective and observational nature of the study 
contributing to an increased risk of bias. A possible explanation for the results might be that PZA 
treatment mainly has its effect in shortening a regimen (7) instead of improving outcomes or that patients 
had sufficient likely effective drugs in their regimen. The generalisability would be limited to settings with 
low HIV prevalence and where there is a high background prevalence of SLD resistance. 
 
 
•  This study provides provocative but insufficient evidence to warrant changing PZA treatment 
protocols, although the evidence relating to PZA for the WHO 2016 guideline is weak.  
•  Until further evidence emerges supporting these findings, it seems prudent to continue 
including PZA in standard MDR-TB regimens unless resistance is certain.  
•  We recommend research into alternative add-on agents in settings with high PZA resistance.  
Methods 
•  Medécins Sans Frontières (MSF) and the  
Ministry of Health, Uzbekistan, collaborated  
since 2003 to provide drug-resistant  
TB treatment within Karakalpakstan,  
Uzbekistan. 
•  Three different programme phases, reflecting  
changing treatment protocols  
(2003, 2009, 2012) (3-5). 
•  PZA testing was conducted on liquid media,  
Bactec Mycobacteria Growth Indicator Tube  
960 system (BD Biosciences, Sparks, MD, USA).  
•  PZA testing conducted: 2003-2006 and 2010-2016. 
•  Inclusion criteria;  
(1) starting treatment between 2003-2013 
(2) microbiological diagnosis of pulmonary MDR-TB by phenotypic drug-susceptibility testing (DST)  
(3) documented treatment outcome in the programme 
PZA was routinely included in MDR-TB regimens and could be stopped according to prevailing 
protocol; 2003 and 2009 – PZA stopped at any time if strain was PZA resistant, 2012 – PZA stopped 
after the intensive phase if strain was PZA resistant.  
 
We designed a retrospective cohort study using a multivariable logistic regression analysis. The primary 
analysis assessed the odds ratio (OR) of a successful outcome (cure or treatment completed) amongst 
patients with PZA-susceptible strains compared to resistant in patients treated with PZA in the intensive 
phase. Throughout the analysis a successful outcome was compared with Failure/Death. The 
secondary analysis assessed the association between a successful outcome and PZA length of 
treatment, amongst patients without a diagnostic PZA DST. Power calculations for the primary analysis 
were performed using an OR 1.6 based on the latest meta-analysis (6), rendering a power of 40%.  
•  2,446 patients fulfilled the inclusion criteria 
•  Male 48.6% (n=1,189), median age 30.5 years (IQR 24-42)  
 
•  Patient isolates had median four resistant drugs at diagnosis (IQR 4-4) and 87.2% (n=2,132) 
had at least five effective drugs in their regimen during the intensive phase.  
 
•  Available PZA DST at diagnosis 34.0% (832/2,446), 73.6% (612/832) PZA resistant strains. 
•  Outcomes: Successful outcome 59.4%, 5.8% died, 11.9% failed and 22.9% lost to follow-up. 
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*142 patients excluded due to having no PZA treatment in full intensive phase, one patient excluded due to unknown X-ray result out of 651 patients with outcome 
Death/Failure/Cure/Treatment completed. †Adjusted for age, sex, previous FLD, cavities on X-ray, programme year and number of resistant drugs at diagnosis.  
‡Two missing values due to unknown smear result. P-values: Wald test.  
Guadalajara, Mexico, 
October 2017 
*157 excluded due to having a PZA DST not defined as diagnostic before starting treatment, four excluded that were only given PZA treatment in continuation 
phase and 339 excluded with outcome Loss to Follow-up out of 1,614 patients with no available PZA DST at diagnosis. † Adjusted for age, sex, previous first-line 
drugs, cavities on X-ray, programme year and number of resistant drugs at diagnosis. P-values: Wald test.  
Standard drugs used in MDR-TB regimens. Photo: Johanna Kuhlin.  
